Search Results

The Microgel Alkaline Hemoglobin Electrophoresis test kit is intended for qualitative and semiquantitative determination of normal hemoglobins (A1, A2 and F) as well as certain abnormal or variant hemoglobins (S or D and C or E) using agarose gel. To distinguish hemoglobins S from D or C from E an alternate confirmatory test such as acid hemoglish hemoglobin electrophoresis is necessary. The electrophoretic test is performed at allialine pH and provides a valuable screening method for hemoglobin patterns. Densitometry of the pattern allows the relative quantification of hemogram patism belief allows the pattern allows the relative automated Microod instrument automated Microgel instrument.

The Microgel Acid Hemoglobin Electrophoresis kit is a qualitative test for the identification of both normal and abnomal or variant hemoglobins, and to confirm the identify of clinication of hemoglobins such as A. E. Gand O. Th hemoglobins such as A, F, S and C. The Acid Hemoglobin test kit employs agarose gel at acidic pH and is for in vitro diagnes and of The Rold Hemoglouin test Kit Employs agarose gel at acidid Microgel instrument Microgel instrument.

Not Found

The provided text does not contain detailed information about the acceptance criteria or a study proving the device meets those criteria. It is a 510(k) clearance letter for the "Microgel Hemoglobin Test Systems by Electrophoresis."

This document primarily states:

• The device name and its regulatory classification.
• That the device has been found substantially equivalent to legally marketed predicate devices.
• The intended use of the device, which includes qualitative and semi-quantitative determination of various hemoglobins using electrophoresis.
• General regulatory requirements.

Therefore, I cannot provide the requested information, including:

1. A table of acceptance criteria and reported device performance.
2. Sample size for the test set and data provenance.
3. Number and qualifications of experts for ground truth.
4. Adjudication method.
5. MRMC comparative effectiveness study results.
6. Standalone performance details.
7. Type of ground truth used.
8. Sample size for the training set.
9. How ground truth for the training set was established.

This type of detailed performance data is typically found in the full 510(k) submission, not summarized in the clearance letter itself.

Ask a specific question about this device

The Interlab Alkaline Hemoglobin Electrophoresis test system is intended for the separation of normal hemoglobins (A1, A2 and F) as well as certain abnormal or variant hemoglobins (S or D and C or E) using cellulose acetate supported on Mylar®. The test is a screening method for in vitro diagnostic use on the Microtech 672 PC and the Microtech 648 ISO fully automated analyzers. To distinguish hemoglobins S from D or C from E an alternate confirmatory test such as acid hemoglobin electrophoresis is necessary.

The InterLab Hemoglobin devices test kits for the electrophoretic separation of hemoglobin in whole blood and are intended for In-Vitro diagnostic use only. The InterLab Alkaline Hemoglobin Electrophoresis Test Devices provide semi-quantitative identification of hemoglobin bands visualized by staining of the fractions. The principle of hemoglobin electrophoresis is based upon the visualization of specific hemoglobin bands following separation by electrophoresis. Dilutions of a patient's specimen are placed on separate tracks (fingers) on a cellulose acetate slide six fingers shaped, and the major hemoglobin groups are separated by electrophoresis. The migration rate depends on the temperature, pH, ionic force of the solution and proportions of the reactants. After electrophoresis, the slide is processed to remove excess soluble materials through a washing step. Fractionated hemoglobins are stained. The excess of stain is removed by a destaining step.

Here's an analysis of the provided text, outlining the acceptance criteria and the study that demonstrates the device meets them:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are implicitly defined by the comparison to a commercially available reference method and the statistical results (correlation coefficients, precision metrics) achieved.

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size: 93 samples (from both normal and suspected pathological patients).
• Data Provenance: Retrospective, as samples were "submitted for routine testing to the hospital laboratory." The country of origin is not explicitly stated.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

The document does not explicitly state the number of experts or their qualifications. It mentions that comparative studies were done against "the laboratory's routine commercially available agarose gel test system following the manufacturers' procedure." This implies that the results from the reference method, presumably interpreted by qualified laboratory personnel, served as the ground truth.

4. Adjudication Method for the Test Set

The document does not describe a formal adjudication method (e.g., 2+1, 3+1). The "ground truth" seems to be established by the results of the reference agarose gel test, which implies a single reference result per sample rather than a consensus among multiple readers for the test set itself.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance

No, a multi-reader multi-case (MRMC) comparative effectiveness study was not indicated. This device is an in-vitro diagnostic test system for semi-quantitative identification of hemoglobin bands, not an AI-assisted diagnostic tool that aids human readers. The comparison is between two laboratory testing methods.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

The device is described as an "electrophoretic hemoglobin analysis system" that performs semi-quantitative identification of bands after processing. While it runs on "fully automated analyzers" (Microtech 672 PC and Microtech 648 ISO), the identification of bands and their comparison to a reference method (agarose gel test) implies that the system outputs results, and these results (band patterns) are then visually inspected and compared. The study data focuses on the performance of the test system itself, suggesting standalone performance in generating the patterns. However, the qualitative assessment ("visually inspected") suggests human interpretation is still involved in confirming results against the reference.

7. The Type of Ground Truth Used

The ground truth for the method comparison and agreement studies was established by a reference method, specifically "the laboratory's routine commercially available agarose gel test system."

8. The Sample Size for the Training Set

The document does not mention the use of a separate training set. The study described uses 93 samples for performance evaluation, compared against a reference method. This appears to be a validation/verification study, not a development study involving a distinct training phase for an algorithm.

9. How the Ground Truth for the Training Set Was Established

As no training set is mentioned for an algorithm, this question is not applicable to the provided information.

Ask a specific question about this device

The Acid Hemoglobin system is intended as a qualitative screening method for the presence of abnormal hemoglobins such as HbS, HbC or HbF using agar electrophoresis.

The system will provide two kits for use on the REP, REP 3 and the SPIFE electrophoresis analyzers.

Not Found

I am sorry, but the provided text is a letter from the FDA regarding a 510(k) premarket notification for an "Acid Hemoglobin Kit." This document does not contain any information about the acceptance criteria, device performance, sample sizes, expert qualifications, or study details that you have requested.

Therefore, I cannot fulfill your request to describe the acceptance criteria and the study proving the device meets them based on the given text.

Ask a specific question about this device

Sebia's HYDRAGEL HEMOGLOBIN(E) and HYDRAGEL ACID(E) HEMOGLOBIN(E) lines of devices are intended as an aid in the detection and identification of human hemoglobin abnormalities, namely hemoglobinopathies (structural hemoglobin abnormalities) and thalassemias (regulation abnormalities). The uses are indicated as follows:

The HYDRAGEL HEMOGLOBIN(E) and HYDRAGEL MINI HEMOGLOBIN(E) Kits are designed for use in conjunction with a manual electrophoretic apparatus. The HYDRAGEL 7/15 HEMOGLOBIN(E) Kits are designed for use with the semi-automated HYDRASYS electrophoretic apparatus. All these kits utilize alkaline agarose gels for electrophoretic separation of human hemoglobins. The electrophoregrams are interpreted visually for pattern abnormalities. Densitometry can serve as an aid in the interpretation by providing relative concentrations of individual fractions. The kits are intended for the normal hemoglobins (A and A2) and the major hemoglobin variants S or D and C or E. They are indicated for screening for clinically important abnormal hemoglobins. Electrophoresis on acidic gel, e.g., HYDRAGEL ACID(E) HEMOGLOBIN(E), should follow to confirm the identification of hemoglobin variants, in particular, to differentiate hemoglobins S from D and E from C.

The HYDRAGEL ACID(E) HEMOGLOBIN(E) and HYDRAGEL MINI ACID(E) HEMOGLOBIN(E) Kits are designed for use in conjunction with a manual electrophoretic apparatus. The HYDRAGEL 7/15 ACID(E) HEMOGLOBIN(E) Kits are designed for use with the semi-automated HYDRASYS electrophoretic apparatus. All these kits utilize acid buffered agarose gels for electrophoretic separation of human hemoglobins. The electrophoregrams serve for qualitative, visual interpretation of the patterns. The kits are indicated for confirming the identity of clinically important abnormal hemoglobins that have been previously detected on alkaline buffered HYDRAGEL HEMOGLOBIN(E) gels. Primarily, they serve for differentiation of hemoglobins S from D and E from C.

Not Found

This document is a 510(k) premarket notification from the FDA for a device called HYDRAGEL Hemoglobin (E). It does not contain the detailed information necessary to answer all aspects of your request. The document describes the device's intended use and FDA's determination of substantial equivalence to predicate devices, but it does not detail a study conducted to establish acceptance criteria or demonstrate performance in the way a clinical trial report would.

However, I can extract some information based on the typical regulatory context of such devices.

Here's what can be inferred or directly stated from the provided text, along with what cannot be answered:

1. A table of acceptance criteria and the reported device performance

This information is not present in the provided 510(k) summary. A 510(k) often focuses on demonstrating substantial equivalence to a predicate device rather than detailing specific acceptance criteria and performance data from a new, standalone study for the device itself. The document mentions "electrophoregrams are interpreted visually for pattern abnormalities" and "Densitometry can serve as an aid in the interpretation by providing relative concentrations of individual fractions," which are methods of interpretation, but not performance metrics or acceptance criteria.

2. Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective)

This information is not present in the provided 510(k) summary.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g., radiologist with 10 years of experience)

This information is not present in the provided 510(k) summary. The document states that "electrophoregrams are interpreted visually for pattern abnormalities," implying human interpretation, but does not specify the number or qualifications of interpreters.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set

This information is not present in the provided 510(k) summary.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

This information is not present in the provided 510(k) summary. The device described (HYDRAGEL Hemoglobin (E)) is an in vitro diagnostic electrophoresis kit, and as such, it predates widespread AI assistance in this specific application. The document describes visual interpretation and densitometry, which are human-centric methods.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This information is not present in the provided 510(k) summary. Given the nature of the device as an electrophoresis kit with visual interpretation, it's highly unlikely that a standalone algorithm-only performance study was conducted or would even be relevant.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

This information is not explicitly stated in the provided 510(k) summary. However, for a device intended to aid in the detection and identification of hemoglobin abnormalities, the ground truth would typically be established by:

• Reference methods: Other established, highly accurate laboratory tests for hemoglobin variants.
• Clinical diagnosis: Confirmation through patient clinical presentation and other diagnostic findings.
• Expert interpretation: Consensual agreement among experienced laboratory professionals specializing in hemoglobinopathies.
  The document states the device is intended for "screening for clinically important abnormal hemoglobins" and "confirming the identity of clinically important abnormal hemoglobins," implying that the outcome of these tests would need to align with established clinical knowledge.

8. The sample size for the training set

This information is not present in the provided 510(k) summary. This type of device (electrophoresis kit) is not "trained" in the machine learning sense. Its performance relies on the biochemical principles of electrophoresis and the reagents provided.

9. How the ground truth for the training set was established

This question is not applicable as there is no "training set" in the context of this device. The device itself (the kit and electrophoretic method) is the "system," and its performance is evaluated against established diagnostic accuracy, not by training an algorithm.

Ask a specific question about this device

The SPIFE Alkaline Hemoglobin system is intended for the qualitative and semi-quantitative determination of abnormal hemoglobins using agarose electrophoresis on the SPIFE Analyzer. The system is used as a screening method for in vitro diagnostic use.

Not Found

I am sorry, but the provided text does not contain the detailed information necessary to describe the acceptance criteria and the study that proves the device meets the acceptance criteria. The document is a 510(k) clearance letter for the SPIFE Alkaline Hemoglobin Kit, indicating that the FDA has found the device substantially equivalent to a legally marketed predicate device.

The letter itself does not include:

• A table of acceptance criteria or reported device performance.
• Information on sample sizes for test or training sets, nor data provenance.
• Details on the number or qualifications of experts, or adjudication methods for ground truth.
• Whether MRMC or standalone studies were performed, or any associated effect sizes.
• The type of ground truth used.

Essentially, this document is the outcome of a regulatory review, not the detailed study report or performance data that would have been submitted as part of the 510(k) application. To answer your questions, I would need a different type of document, such as the full 510(k) submission or a peer-reviewed publication detailing the device's validation studies.

Ask a specific question about this device